Aminoalkyl substituted 5,6,7,8-tetrahydro-9H-pyridino [2, 3-B] indole and 5,6,7,8-tetrahydro-9H-pyrimidino [4, 5-B] indole derivatives: CRF1 specific ligands
申请人:Neurogen Corporation
公开号:US06291473B1
公开(公告)日:2001-09-18
Disclosed are compounds of the formula:
wherein
Ar, R1, W, X and m are substituents as defined herein.
These compounds are modulators of CRF receptors and are therefore useful for treating affective disorder, anxiety, depression, headache, irritable bowel syndrome, post-traumatic stress disorder, supranuclear palsy, immune suppression, Alzheimer's disease, gastrointestinal diseases, anorexia nervosa or other feeding disorder, drug addiction, drug or alcohol withdrawal symptoms, inflammatory diseases, cardiovascular or heart-related diseases, fertility problems, human immunodeficiency virus infections, hemorrhagic stress, obesity, infertility, head and spinal cord traumas, epilepsy, stroke, ulcers, amyotrophic lateral sclerosis, hypoglycemia or a disorder the treatment of which can be effected or facilitated by antagonizing CRF, including but not limited to disorders induced or facilitated by CRF, in mammals, comprising: administering to the mammal a therapeutically effective amount of a compound of Formula I.
本发明涉及一种化合物,其化学式为:其中Ar,R1,W,X和m是定义如下的取代基。这些化合物是CRF受体调节剂,因此可用于治疗情感障碍、焦虑、抑郁、头痛、肠易激综合征、创伤后应激障碍、上核性麻痹、免疫抑制、阿尔茨海默病、胃肠疾病、厌食症或其他进食障碍、药物成瘾、药物或酒精戒断症状、炎症性疾病、心血管或心脏相关疾病、生育问题、人类免疫缺陷病毒感染、出血应激、肥胖症、不孕不育、头部和脊髓创伤、癫痫、中风、溃疡、肌萎缩性侧索硬化、低血糖或可通过拮抗CRF来影响或促进治疗的疾病,包括但不限于由CRF引起或促进的哺乳动物疾病:向哺乳动物施用化合物I的治疗有效量。